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OBJECTIVE: The significance of pretransplant, donor-specific antibodies on long-term patient outcomes is a subject
of debate. This study evaluated the impact and the presence or absence of donor-specific antibodies after kidney
transplantation on short- and long-term graft outcomes.
METHODS: We analyzed the frequency and dynamics of pretransplant donor-specific antibodies following renal
transplantation from a randomized trial that was conducted from 2002 to 2004 and correlated these findings with
patient outcomes through 2009. Transplants were performed against a complement-dependent T- and B-negative
crossmatch. Pre- and posttransplant sera were available from 94 of the 118 patients (80%). Antibodies were
detected using a solid-phase (LuminexH), single-bead assay, and all tests were performed simultaneously.
RESULTS: Sixteen patients exhibited pretransplant donor-specific antibodies, but only 3 of these patients (19%)
developed antibody-mediated rejection and 2 of them experienced early graft losses. Excluding these 2 losses, 6 of
14 patients exhibited donor-specific antibodies at the final follow-up exam, whereas 8 of these patients (57%)
exhibited complete clearance of the donor-specific antibodies. Five other patients developed ‘‘de novo’’
posttransplant donor-specific antibodies. Death-censored graft survival was similar in patients with pretransplant
donor-specific and non-donor-specific antibodies after a mean follow-up period of 70 months.
CONCLUSION: Pretransplant donor-specific antibodies with a negative complement-dependent cytotoxicity
crossmatch are associated with a risk for the development of antibody-mediated rejection, although survival rates
are similar when patients transpose the first months after receiving the graft. Our data also suggest that early
posttransplant donor-specific antibody monitoring should increase knowledge of antibody dynamics and their
impact on long-term graft outcome.
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INTRODUCTION
The introduction of solid-phase assays for the detection of
anti-HLA antibodies (ABs) as well as C4d staining for the
evaluation of allograft biopsies has revolutionized the
current era of assessing acute and chronic donor-specific
antibody-mediated rejection in clinical practice.
Preformed, donor-specific HLA ABs (DSA) are respon-
sible for some renal allograft rejections. The detection of
these ABs prior to transplantation is an important step in the
assessment of a patient’s immunological risk and the
exclusion of incompatible donors.
However, these new methods used for antibody recogni-
tion are performed in special in vitro conditions that may
not accurately reflect conditions in vivo. Pre-Tx HLA-DSA
are not necessarily harmful to the transplanted kidney, and
these ABs may also preclude the implant of a transplantable
organ due to a new technological barrier.
The relevance of pre-TX DSA in patients with a negative
crossmatch remains controversial (1-5). These discrepant
results may be due to the dynamics of DSA generation.
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Following transplantation, the blood levels of DSA may
increase, decrease or be completely cleared from the
recipient’s blood post-transplantation, and these changes
may therefore impact graft outcomes.
A prospective trial to assess the impact of DSA dynamics
on allograft outcome is a high-risk and potentially unethical
study.
Therefore, the current study examined previously frozen
and stored sera from a retrospective population of renal
patients who had received transplants with a negative
complement-dependent cytotoxicity crossmatch (CDC-XM).
As the currently used assays were unavailable at the time of
serum collection, the current study examined these retro-
spective samples using modern solid-phase assays.
This cross-sectional study analyzed the frequency of pre-
Tx DSA and the presence/absence of these ABs following
Tx using single antigen beads to assess the short- and long-
term outcomes of MoDIFY trial participants who received
transplants between 2002 and 2004.
METHODS
Patients
Male and female patients between the ages of 18 and 65
years who had received a non-identical twin kidney
allograft and who presented an ELISA panel-reactive
antibody (PRA) level ,50% during a prospective, rando-
mized and controlled trial of tacrolimus (TCL) (PrografH,
Astellas, Deerfield, IL, USA) minimization (the MoDIFY
study - Modification of Doses to Improve Function through
the Years) (6) were eligible for the current trial. Subjects
were excluded if they had received a nonrenal organ or
induction with antilymphocyte preparations.
Subjects who fulfilled the inclusion criteria were rando-
mized (2:1) to receive TCL at either an initial dose of 0.15 -
0.25 mg/kg/day or a cyclosporine microemulsion (NeoralH,
Novartis Pharma, USA) at an initial dose of 10 mg/kg/day.
Drug doses were subsequently adjusted according to the
whole blood levels. For patients in the TCL groups, target
pre-dose (C0) levels were 10-15 ng/mL during the first
month of treatment but progressively decreased to 3-5 ng/
mL at 6 months. In the CyA group, the dose was adjusted
according to the CyA concentration during the second hour
(C2) following the oral dose, and the target concentrations
were between 1,400 and 1,700 ng/mL during the first month
and between 800 and 1,000 ng/mL after 6 months. All
patients received 1.5 to 2 g/day mycophenolate mofetil
(MMF) (CellceptH, Hoffman La Roche). All groups received
an initial dose of 0.5 mg/kg/day prednisone, which was
tapered to 0.1 mg/kg/day prior to the third month of
treatment. TCL, CyA and MMF were administered in two
12 h interval oral doses, typically at 8 a.m. and 8 p.m. All
patients received induction with an anti-IL2R antibody,
either basiliximab (SimulectH, Novartis Pharma) or daclizu-
mab (ZenapaxH, Hoffman La Roche). The Institutional
Ethics Committee approved this study, which was also
conducted in full compliance with the Guidelines for Good
Clinical Practices.
Renal biopsies
Available biopsies from patients with acute allograft
dysfunction were reviewed according to the Banff 2007
classification (7). C4d staining was performed using IHC
(immunohistochemistry) from paraffin-embedded biopsies.
Staining of more than 10% of the PTC (peritubular
capillaries) was considered positive, as this has been
shown to correlate with graft loss and the presence of
DSA (8,9).
HLA typing
All donors and recipients were typed for HLA-A, -B and
-DR using low-resolution polymerase chain reaction
single-strand polymorphisms (PCR-SSPs) (One Lambda,
Canoga Park, CA). HLA-DP, -DQ and -Cw specificities
were not examined in this study because these antigens
were not routinely typed in our region at that time. Donors
and recipients were also not typed for these loci because it
was not possible to re-type all of the donors for these
antigens.
Pretransplant crossmatch
All patients exhibited negative pretransplant CDC-XM
with antihuman globulin CDC (CDC-AHG-XM) for T cells
and long-incubation CDC for B cells at the time of
transplantation. The presence of IgM antibodies was
excluded by testing for CDC-XM in the presence of
dithiothreitol (DTT).
Pre- and post-Tx serum collection
Two serum samples from each patient were analyzed, one
pre-Tx and the other either after the last follow-up exam or
prior to death or graft loss. Serum was collected from all
MoDIFY study participants prior to Tx and was stored
frozen (-70˚ C). The second serum samples (post-Tx) were
collected under the following conditions: 1 - posttransplant
serum was collected from active patients who agreed to
participate at the time of providing informed consent; 2 -
patients who returned for dialysis were invited to partici-
pate; and 3 - the hospital laboratories were searched for sera
samples that had been collected and frozen from patients
who had died with a functioning graft.
Panel-reactive antibodies (PRAs)
PRA levels (% PRA) were measured using flow cytometry
for the detection of anti-HLA class I and II antibodies, as
recommended by the manufacturers.
Donor-specific antibodies (DSAs)
All patients were tested for the presence of DSA in pre-
and posttransplant sera using a solid-phase assay consisting
of a single HLA antigen-coated microspheres (LuminexH -
One Lambda, Canoga Park, CA). Briefly, 5 ml of class I and
class II beads were mixed with 20 ml of the serum sample,
and the mixture was incubated in the dark for 30 minutes at
room temperature. After 3 washes, 100 ml of 1:100 FITC goat
antihuman IgG was added, and the samples were incubated
at the same conditions for 30 minutes. The microbeads were
washed twice and resuspended in 80 ml of fixing solution.
Class I and II antibodies were distinguished using a single
test, and the tests were read on the LABScreenTM100
Luminex machine (One Lambda, Inc.).
The immunodominant DSA (iDSA), i.e., the antidonor
HLA antibody with the highest median fluorescent intensity
(MFI), was used for the statistical analysis when more than
one antibody was detected. The charts display each of the
recipients’ DSA-MFIs in addition to the iMFIs.
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DATA ANALYSIS
Delayed graft function was defined as the need for dialysis
during the first week after transplantation. Any cases with the
detection of Cytomegalovirus disease (syndrome or invasive)
were classified as CMV-positive. Rejection was defined as any
treated or biopsy-proven acute rejection episode. Additional
variables that were used for the statistical analysis included
the following: recipient and donor age, gender, race, number
of HLA-A, -B and -DR incompatibilities, deceased/live donor,
type of IL-2R AB administered, doses and blood levels of IS
drugs (TCL, CyA and MPA) at 1, 3, 6 and 12 months and 2, 3, 4
and 5 years after Tx, serum creatinine level, eGFR (estimated
glomerular filtration rate) according to the MDRD equation
and the urinary protein/creatinine from the same time-points
as when the immunosuppressive drugs levels were measured.
Data are reported as the means¡SD, and the medians
and 95% C.I. are reported for nonparametric data. Data were
analyzed during the first 6 months to identify an early
impact of DSA, and the data were re-analyzed to verify the
long-term impact of DSA on long-term allograft outcomes
for grafts that had survived the first 6 months. Cox
proportional analysis evaluated the hazards of each avail-
able variable to predict death-censored graft survival. The
PASW statistics 18 (SPSS) software was used for the
statistical analyses.
RESULTS
Study population
Twenty-four of the 118 patients in the Modify study did
not participate in this analysis. Fifteen patients lost their
grafts during the first year due to vascular reasons and/or
renal rupture (n = 5), death (n = 8) or acute rejection (n = 2).
No available post-Tx serum samples were available for
these patients. A post-Tx serum sample was also not
available for one patient who died after 7 years of follow-
up. Eight patients with functioning grafts at the time of
Figure 1 - Pre- and posttransplant MFIs of each of the detected DSAs in 11 patients who remained active until the last follow-up visit
(figure 1a) and in 5 patients who lost their allografts or died (figure 1b). The dotted line represents the standard cut-off MFI value for
this method.
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enrollment refused to participate in the study. Therefore, 94
patients (80%) from the MoDIFY study population were
analyzed.
Time of pre- and post-Tx sera collection
Pre-Tx sera were collected and frozen at a median of 61
(-134 to 30) days prior to Tx.
Post-Tx sera were collected from all 75 active patients at
our outpatient clinic at a mean of 1834 ¡ 389 days
posttransplant. Nine patients died with a functioning graft
at a mean of 1080¡810 days after Tx, and post-Tx serum
samples were collected at a mean of -613 ¡ 623 days prior
to death.
Ten patients lost their grafts and returned to dialysis.
Serum samples were collected from two of these patients at
38 and 222 days prior to graft loss. The remaining 8 cases
were recruited from dialysis facilities for the collection of
sera at a median of 836 [303–1,114] days after graft loss.
Donor-Specific Antibodies (DSA)
Sixteen of the 94 study patients (17%) were transplanted
with DSA (pre-Tx DSA), and 78 patients (83%) were
transplanted without DSA (no DSA).
Table 1 describes the demographics and transplant
characteristics of the study population.
The pre-Tx DSA and no DSA groups were similar at
baseline, although more patients in the pre-Tx DSA group
exhibited a PRA class I and II level above 0% as well as a
higher class I and II PRA percentage. The numbers of
biopsy-proven AR (BPAR) and AMR cases were signifi-
cantly higher in the pre-Tx DSA-positive group.
Patients with pre-Tx antibodies
Table 2 lists the DSA specificities, MFIs and outcomes of
patients who received transplants with pre-Tx DSA. Twelve
pts (75%) exhibited anti-HLA class I antibodies, three
patients (19%) exhibited anti-class II antibodies, and one
patient exhibited (6%) both class I and II ABs.
Ten of these 16 (62%) patients did not develop acute
rejection episodes (AR), whereas six (38%) patients devel-
oped ARs, including one patient with a late AR episode on
PO day 797. The biopsies revealed that only three (3%)
patients in the pre-Tx DSA group developed the full clinical
picture of antibody-mediated rejection (AMR) with C4d-
positive staining in peritubular capillaries. No cases of
hyperacute rejection were observed. The cases with ARs
were classified as AMR (n = 3), Banff Ib (n = 1), Banff IIa
(n = 1), or clinically diagnosed but not biopsied (n = 1). The
three cases of AMR were treated with thymoglobulin, and
two of these cases were also treated with intravenous
immunoglobulin between 2002 and 2004 due to the
diagnosis of ‘‘acute transplant vasculopathy’’ that suggested
a ‘‘humoral’’ component of the AR. Two of the three
patients with AMR lost their allografts. AMR only occurred
in patients with class I DSA, as none of the three patients
with only class II DSA developed AMR.
The mean iMFI-DSA did not differ between pre-Tx DSA
patients who developed AMR (n = 3) and those patients who
did not develop AMR (n = 13) (6106¡6600 vs 5423¡2910,
p =NS, respectively, p=NS). The same results were
observed when comparing patients who developed AR
(AMR or not, n = 6) to those who did not develop AR (n = 10)
(6609¡4948 vs 4917¡2511, respectively, p=NS). A ROC
curve analysis did not identify a cut-off MFI for pre-Tx DSA
that could predict the development of AMR.
Two patients, of the 14 pts with pre-Tx DSA who survived
the first six months after transplantation, died with a
functioning graft (DwFG) at 23 and 72 months posttrans-
plantation, and one patient lost his/her graft due to chronic
transplant nephropathy at 49 months posttransplantation.
Profile of pre- and posttransplant DSA frequencies
and outcomes
The post-Tx DSA evaluation from the last follow-up visit,
excluding the two patients who lost their allografts due to
early AMR, revealed that six of the 14 patients demon-
strated DSA, whereas eight patients had completely cleared
the DSA (Figure 1A and 1B). Seven patients had cleared
class I DSA and one patient had cleared class II DSA.
Changes in DSA specificities were observed in three cases
(patients # 1, 13, and 16 in Table 2).
Patients who had completely cleared the DSA were not
significantly different from patients who had not cleared the
DSA in regards to all baseline variables, including the pre-
Tx class I PRA level (22¡29 vs. 8¡14%, respectively,
p =NS) and class II PRA level (26¡37 vs. 21¡ 29%,
respectively, p=NS). The pre-Tx immunodominant MFI-
DSA (iMFI-DSA) was not different among patients who had
cleared the DSA, as compared to patients who had not
(6371¡2773 vs. 3503¡2607, respectively, p= 0.07). The oral
dose and blood level of the IS drugs were not different at 1,
3, 6, and 12 months or 2, 3, 4, and 5 years post-Tx between
these two groups.
Overall graft survival for pre-Tx DSA-positive patients
was lower than for patients without pre-Tx DSA, although
this difference was not statistically significant (Log
Rank = 0.21) (Figure 2). Death-censored graft survival was
similar between the two groups, and renal function was also
Table 1 - Demographics and transplant characteristics of
the study population.
No pre-Tx
DSA
Pre-Tx
DSA p-value
n 78 (83%) 16 (17%)
Gender (F/M) 33/45 10/6 NS
Race (white/no white) 55/23 11/5 NS
Age (years) 42¡12 40¡12 NS
Tx (1st/pre-Tx) 74/4 13/3 0.093
Donor (D/L) 39/39 13/3 0.028
PRA cl-I (+) 11 (15%) 10 (62%) ,0.001
% PRA cl-I 2¡7 18¡23 0.000
PRA cl-II (+) 8 (10%) 7 (44%) 0.003
% PRA cl-II 3¡11 26¡35 0.000
TCL/CyA (n= ) 53/25 11/5 NS
HLA-A mm (0/1/2) 14/37/27 0/9/7 NS
HLA-B mm (0/1/2) 10/42/26 0/7/9 NS
HLA-DR mm (0/1/2) 23/39/14 6/8/2 NS
AR (clinical) 16 (20%) 6 (38%) NS
BPAR 8 (10%) 5 (31%) 0.046
AMR 0 (0%) 3 (19%) 0.004
DGF
(in deceased donor)
24 (61%) 8 (50%) NS
CMV 17 (22%) 4 (25%) NS
Follow-up (mo) 69¡16 70¡15 NS
AR: clinically diagnosed acute rejection episodes; BPAR: biopsy-proven
acute rejection episodes; AMR: antibody-mediated rejection; DGF:
delayed graft function; CMV: cytomegalovirus disease; TCL: tacrolimus;
CyA: Cyclosporin-A.
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similar between patients with and without pre-Tx
DSA (64¡15 vs 58¡22 ml/min, respectively, p=NS).
Additionally, the urinary P/Cr levels did not differ between
non-pre-Tx DSA patients and pre-Tx DSA-positive patients
(0.49¡0.83 vs. 0.86¡1.1, respectively, p =NS).
A Cox univariate analysis revealed that the only variable
with a risk for death-censored graft loss was the presence of
a positive post-Tx DSA, including patients with ‘‘de novo’’
post-Tx DSA and patients with early graft loss due to AMR
(HR: 5.1, 1.4-18.1, p= 0.012). The presence of pre-Tx DSA for
class I and/or II was not associated with a risk of death-
censored graft loss (p= 0.297).
DISCUSSION
This cross-sectional study analyzed the impact of pre-Tx
DSA on the long-term outcomes of patients in a low-risk
renal transplant population.
The novel aspect of our study was the analysis of post-Tx
DSA, which revealed the dynamics of pre-Tx DSA
responses after transplantation.
The first finding of our study was that the majority of
patients with low levels of pre-Tx DSA did not develop
AMR. However, occurrences of AMR were most often
severe and frequently led to early graft loss. The incidence
of AMR in our study (19%) was lower than that in previous
studies, particularly in patients with strongly positive DSA
and a historic positive cross-match (10). One explanation for
this result could have been the low levels of DSA in our
population, which were evidenced by the negative pre-Tx
CDC-XMs of the included patients. The AMR rates vary
between studies; in one large retrospective study, the
prevalence of AMR was only 2%, and all patients with
AMR had at least one strong donor-specific DSA with an
MFI value greater than 6,000 (11).
However, the disparity in AMR rates between studies may
be due to the absence of protocol biopsies for the diagnosis of
subclinical AMR. A cohort study of 54 DSA-positive kidney
transplant recipients demonstrated that 31% of patients met
the criteria for subclinical antibody-mediated rejection
(SAMR) at the time of a three-month protocol biopsy (12).
We used the BANFF-2007 classification, which requires
positive C4d staining for an AMR diagnosis. We also
performed C4d staining retrospectively using IHC. As IF is
more sensitive than IHC (13,14), we may have under-
diagnosed cases of AMR due to the false-negative C4d
staining using IHC and the absence of protocol biopsies.
Table 2 - HLA-DSA and outcomes.
Pre-Tx Post-Tx
Patient
# cl - I MFI-Cl -I cl -II
MFI
cl -II
AR(Banff)
PO day
Day of serum
harvest
prior to death and
after loss cl-I MIF Cl-I cl -II MIF cl -II
Outcome
/cause/
Fup (months)
1 A33 3169 DR1 2913 AMR I
13PO
+1151 A33 10047 DR1 DR7 7727
4090
GL/AMR
2
2 B7 13666 -- -- AMR II
28PO
+1710 B7 1472 -- -- GL/AMR
4
3 A30 10122 -- -- AR clinical
13 PO
+600 -- -- -- -- GL/CAN
49
4 A31 800 -- -- No AR -324 A31 612 -- -- DwFG/
Suicide
23
5 B44 7322 -- -- No AR -134 B44 6584 -- -- DwFG/
Infection
72
6 A11 4583 -- -- No AR -- -- -- -- -- Active
62
7 B14 7173 -- -- No AR -- -- -- -- -- Active
62
8 A68 5215 -- -- No AR -- -- -- -- -- Active
62
9 A31 1050 -- -- No AR -- A31 871 -- -- Active
72
10 A23 8312 -- -- No AR -- -- -- -- -- Active
73
11 B51
A26
1485
1047
-- -- AMR I
27PO
-- -- -- -- -- Active
73
12 -- -- DR103 5297 No AR -- -- -- -- -- Active
76
13 -- -- DR16
DR1
1048
5721
No AR -- A31 1215 -- -- Active
77
14 A2
A29
8782
3148
-- -- Ib
797 PO
-- -- -- -- -- Active
79
15 A11 2429 -- -- IIa
6PO
-- A11 2325 -- -- Active
81
16 -- -- DR4 3703 No AR -- A68 886 DR53 14377 Active
84
class I and class II: Donor-specific anti-HLA antibodies anti-class I and anti-class II; MFI: median fluorescent intensity; AMR: antibody-mediated rejection;
GL: graft loss; DwFG: death with a functioning graft; CAN: chronic allograft nephropathy; Fup: follow-up.
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However, our results also suggest that patients with low
levels of pre-Tx DSA rarely develop AMR, which suggests
the possibility of an association between a low concentration
of pre-Tx DSA and a negative CDC-XM. This rationale is
consistent with previous data demonstrating an association
between assay results and, graft loss (15). A retrospective
analysis of transplanted patients who had a negative CDC-
XM but positive results from a solid-phase assay or FCXM
revealed that most patients neither developed AMR
episodes nor exhibited impaired graft survival (5).
However, two of the three patients who developed AMR
lost their grafts. Unfortunately, it was not possible to retest
the pre-Tx sera against the donor lymphocytes to perform
FCXM in our population.
Whether pre-Tx DSA-MFI levels can predict the develop-
ment of AMR is an additional topic of debate. The
prevalence of AMR increases with increasing pre-Tx DSA-
MFIs, and a peak serum MFI between 465 and 1500 in the
peak serum is associated with a 25-fold increase in the
relative risk for the development of AMR (10). However, we
could not detect a pre-Tx MFI cutoff value that could predict
the occurrence of AMR. The reasons for these discrepant
results remain unclear, although the examination of only
pre-Tx serum, rather than serum from the peak of the
response, may provide one explanation.
Another important finding of our study was related to the
discordance between previous studies as to the impact of
pre-Tx DSA levels (not detected by CDC-XM) on transplant
outcome. Some authors have observed worse outcomes,
whereas others have not (5,10,16). A retrospective study was
performed on 113 kidney transplant recipients with nega-
tive prospective T- and B-cell CDC-XM at the time of
transplant, and these patients were screened for the
presence of circulating anti-HLA antibodies and DSA using
the Luminex assay. One-year allograft survival rates were
similar between the Luminex pre-Tx DSA-positive and
DSA-negative groups (17). Patients with DSA who did not
experience AMR exhibited the same graft survival rates as
patients without DSA (10), and the results of the current
study are in line with these previous findings.
The major finding of the current study was that differences
in long-term graft survival among individuals with pre-Tx
DSA may be due to the dynamics of the DSA response. This is
the first study to analyze pre- and post-Tx DSA data for the
same patient population and correlate these dynamics with
long-term patient outcome. A large effort was made to collect
blood from patients who returned to dialysis and to search
for frozen serum samples collected from patients prior to
death. We acknowledge that, in many cases, the post-Tx
serum samples were collected in a cross-sectional analysis
many years following transplantation and that this factor
may explain the long-term profile of low-level pre-Tx DSA.
Patients who either completely cleared the DSA post-
transplant or who demonstrated decreased levels of DSA
exhibited similar long-term outcomes as compared to DSA-
negative patients. Therefore, the simple presence of pre-Tx
DSA does not impact transplant outcome, and it seems that
it is critical for outcome that the DSA level remains above a
certain cutoff value post-transplantation.
Patients with DSA who survived the first six months post-
transplant presented a similar long-term outcome as
patients without DSA. These results are consistent with
those of previous studies, although these studies failed to
identify the reasons behind the observed improved out-
come. It is possible that a mean 6-year follow-up period may
not be sufficient for drawing definitive conclusions (5,10).
In summary, this study revealed that the presence of pre-
Tx DSA was initially associated with the occurrence of
AMR, and this condition may lead to graft loss in low-risk
renal patient populations transplanted with a negative CDC
crossmatch. Our data also suggest that early posttransplant
DSA monitoring can improve the understanding of DSA
dynamics. Moreover, pre-Tx DSAs are likely only proble-
matic when these concentrations remain positive after
transplantation and above a certain threshold. However, a
larger post-Tx analysis of pre-Tx DSA-positive patients
would be necessary to prove this hypothesis.
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